U.S. markets closed
  • S&P 500

    3,783.28
    -7.65 (-0.20%)
     
  • Dow 30

    30,273.87
    -42.45 (-0.14%)
     
  • Nasdaq

    11,148.64
    -27.77 (-0.25%)
     
  • Russell 2000

    1,762.69
    -13.07 (-0.74%)
     
  • Crude Oil

    87.99
    +0.23 (+0.26%)
     
  • Gold

    1,724.70
    +3.90 (+0.23%)
     
  • Silver

    20.62
    +0.08 (+0.37%)
     
  • EUR/USD

    0.9894
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • GBP/USD

    1.1332
    +0.0011 (+0.10%)
     
  • USD/JPY

    144.4910
    -0.1190 (-0.08%)
     
  • BTC-USD

    20,145.21
    -136.95 (-0.68%)
     
  • CMC Crypto 200

    456.09
    -2.31 (-0.50%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study

·1 min read
  • AstraZeneca Plc (NASDAQ: AZNreported topline data from the DESTINY-Breast02 phase 3 trial of Enhertu (trastuzumab deruxtecan).

  • The trial evaluated Enhertu versus (trastuzumab/capecitabine or lapatinib/capecitabine) in HER2 positive unresectable and/or metastatic breast cancer previously treated with T-DM1.

  • The trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial also met the key secondary endpoint of improved overall survival.

  • Related: Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation.

  • ENnhertu is a HER2-directed antibody-drug conjugate (ADC) jointly developed and commercialized by Daiichi Sankyo (OTC: DSKNY) and AstraZeneca.

  • The safety profile of Enhertu was consistent with previous phase 3 clinical trials, with no new safety concerns identified. Interstitial lung disease (ILD) rates and severity were consistent observed in other metastatic breast cancer trials of Enhertu.

  • The data will be presented at an upcoming medical meeting.

  • Price Action: AZN shares are up 0.44% at $66.93 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.